The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

Boston Scientific Corp (BSX) stock saw a decline, ending the day at $100.31 which represents a decrease of $-0.60 or -0.59% from the prior close of $100.91. The stock opened at $100.91 and touched a ...

Barclays raised the firm’s price target on Boston Scientific (BSX) to $111 from $86 and keeps an Overweight rating on the shares. The firm says ...

Results from the single-arm trial saw 63.5% of patients able to avoid the symptoms of Atrial fibrillation over the course of ...

Boston Scientific (NYSE: BSX) today reported data from separate studies backing its Farapulse and Watchman FLX systems.

Boston Scientific Corp (BSX) stock saw a modest uptick, ending the day at $98.66 which represents a slight increase of $0.49 or 0.50% from the prior close of $98.17. The stock opened at $97.93 and ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Marie ...

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

Accurate Wealth Management LLC acquired a new stake in shares of Boston Scientific Co. (NYSE:BSX – Free Report) during the ...

Capital Investment Advisors LLC raised its holdings in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 12.2% in ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.

In a recent update, RBC Capital analysts have maintained their Outperform rating on Boston Scientific (NYSE:BSX) shares, with ...